Publikasi Scopus FKUI Tahun 2010 s/d 2020 (data Per 3 Februari 2021)

Arozal W., Watanabe K., Veeraveedu P.T., Ma M., Thandavarayan R.A., Sukumaran V., Suzuki K., Kodama M., Aizawa Y.
32067462200;55492737200;12796732500;7202444988;23390800400;35070365600;55624483910;7403312707;36051317800;
Telmisartan prevents the progression of renal injury in daunorubicin rats with the alteration of angiotensin II and endothelin-1 receptor expression associated with its PPAR-γ agonist actions
2011
Toxicology
279
1-3
91
99
17
Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences, 265-1 Higashijima Akiha-ku, Niigata City 956-8603, Japan; Department of Pharmacology, Faculty of Medicine, University of Indonesia, Jakarta 10430, Indonesia; Department of Gastroenterology and Hepatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata 951-8510, Japan; First Department of Internal Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata 951-8510, Japan
Arozal, W., Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences, 265-1 Higashijima Akiha-ku, Niigata City 956-8603, Japan, Department of Pharmacology, Faculty of Medicine, University of Indonesia, Jakarta 10430, Indonesia; Watanabe, K., Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences, 265-1 Higashijima Akiha-ku, Niigata City 956-8603, Japan; Veeraveedu, P.T., Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences, 265-1 Higashijima Akiha-ku, Niigata City 956-8603, Japan; Ma, M., Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences, 265-1 Higashijima Akiha-ku, Niigata City 956-8603, Japan; Thandavarayan, R.A., Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences, 265-1 Higashijima Akiha-ku, Niigata City 956-8603, Japan; Sukumaran, V., Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences, 265-1 Higashijima Akiha-ku, Niigata City 956-8603, Japan; Suzuki, K., Department of Gastroenterology and Hepatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata 951-8510, Japan; Kodama, M., First Department of Internal Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata 951-8510, Japan; Aizawa, Y., First Department of Internal Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata 951-8510, Japan
Angiotensin II (Ang II) receptor blocker (ARB) suppresses the progression of kidney disease. However, there is limited information regarding the nephroprotective effect of ARB in daunorubicin (DNR)-induced nephrotoxicity in rats. We examined the alteration of the renal Ang II and endothelin-1 (ET-1) receptor expression and the action of telmisartan, an ARB, on DNR-induced nephrotoxicity. Sprague-Dawley rats were treated with a cumulative dose of 9 mg/kg DNR (i.v.). Telmisartan was administered orally every day for 6 weeks. DNR rats showed nephrotoxicity as evidenced by worsening renal function, which was evaluated by measuring protein in urine, levels of urea and creatinine in serum, lipid profiles, malondialdehyde level, and the glutathione peroxidase activity in kidney tissue. These changes were reversed by treatment with telmisartan, which resulted in significant improvement in renal function. Furthermore, telmisartan increased nephrin protein expression, and down-regulated renal expression of Ang II and its receptor Ang II type I. Renal protein expressions of ET-1 and its receptor ET-receptor type A were increased in DNR rats, and treatment with telmisartan attenuated these increased expressions. Telmisartan mediated a further increase in the expression of peroxisome proliferator-activated receptor-γ (PPAR-γ). In addition, the expressions of cyclooxygenase-2 and cellular adhesion molecules were increased in DNR rats, which were attenuated by telmisartan. In conclusion, telmisartan has a protective effect on DNR-induced nephrotoxicity through Ang II and ET-1, with the alteration of their receptor expressions, which is associated with its anti-inflammatory and anti-oxidant effects at least in part through PPAR-γ agonistic actions. © 2010 Elsevier Ireland Ltd.
Angiotensin II receptor; Daunorubicin; Endothelin-1 receptor; Nephrotoxicity; PPAR-γ; Telmisartan
angiotensin receptor; cell adhesion molecule; creatinine; cyclooxygenase 2; daunorubicin; endothelin 1 receptor; endothelin receptor; glutathione peroxidase; malonaldehyde; nephrin; peroxisome proliferator activated receptor gamma; telmisartan; unclassified drug; urea; animal experiment; animal model; animal tissue; article; controlled study; creatinine blood level; drug mechanism; enzyme activity; kidney function; kidney parenchyma; lipid blood level; male; nephrotoxicity; nonhuman; priority journal; protein expression; protein urine level; rat; receptor down regulation; renal protection; Sprague Dawley rat; urea blood level; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antioxidants; Benzimidazoles; Benzoates; Dau
0300483X
TXCYA
20888384
Article
Q1